A rapidly expanding class of weight-loss medications may be doing more than reshaping the obesity landscape — it may also be altering cancer risk.

A new study led by Houston Methodist researchers finds that glucagon-like peptide-1 receptor agonists (GLP-1s) are associated with significantly lower rates of obesity-related cancers among obese adults without diabetes, offering early evidence that these therapies could have broader preventive implications beyond metabolic health.

The findings, based on a large national dataset, suggest a 41% reduction in the cumulative incidence of 13 obesity-associated cancers among obese patients treated with GLP-1 agents compared to those receiving diet and exercise counseling alone.

A new population, a new question

While prior research has explored GLP-1 use in patients with diabetes, this study is among the first to isolate its effects in a distinctly different — and rapidly growing — population: younger, non-diabetic adults using the drugs primarily for weight management.

“We know obesity is increasing at an alarming rate, and with it, the cancers linked to obesity,” says Dr. Aparna Kamat, a gynecologic oncologist at Houston Methodist and senior author of the study. “GLP-1 therapies have transformed how we approach weight loss. What we didn’t know was how these medications might influence cancer risk in obese patients without diabetes.”

To answer that question, the research team used a “target trial emulation” approach — an emerging method designed to approximate the rigor of a randomized clinical trial using real-world data. Leveraging the TriNetX network, which includes health records from more than 113 million patients nationwide, investigators identified more than 229,000 obese adults without diabetes and no prior cancer diagnosis.

Patients receiving GLP-1 therapy were closely matched to those undergoing lifestyle interventions, allowing for a more apples-to-apples comparison.

Signals emerge across cancer types

Over a median follow-up of two years, GLP-1 use was associated with a significantly lower cumulative incidence of cancers known to be linked to obesity, including multiple myeloma, colorectal, endometrial, thyroid and pancreatic cancers.

The magnitude of the association was notable. Overall cancer risk was reduced by 41%, with even larger reductions observed in certain subgroups — including men, where risk dropped by nearly 70%.

Among gynecologic malignancies, the signal was particularly strong for endometrial cancer, a disease closely tied to obesity biology.

“These are early findings, but they’re certainly very compelling,” says Dr. Kamat. “They suggest that beyond weight loss, there may be biologic mechanisms at play — whether through hormonal pathways, inflammation or direct effects on tumor biology — that warrant further investigation.”

Important caveats — and a path forward

Despite the promising results, the authors emphasize that the study was observational and designed to assess short-term cancer incidence, not long-term prevention.

The median follow-up of two years is relatively brief for cancers that often develop over decades. While sensitivity analyses — including exclusion of early cancer diagnoses — supported the findings, the possibility of residual confounding remains.

Notably, the association was not observed across all populations. The study did not find a statistically significant reduction in cancer incidence among Black patients, a disparity that may reflect differences in access to care, underlying risk profiles or other unmeasured factors.

“We cannot say these drugs prevent cancer,” Dr. Kamat cautions. “What we can say is that there is a strong association — and that should be a signal to the research community to study these findings prospectively.”

Clinical implications taking shape

As GLP-1 therapies continue their rapid adoption, oncologists and other clinicians are increasingly encountering patients already receiving these agents. For many, the question is no longer whether to use them but what their broader impact might be.

This study adds to a growing body of evidence suggesting that the benefits of GLP-1 therapy may extend well beyond glycemic control and weight reduction.

For clinicians, the takeaway is not yet a change in practice but a shift in perspective.

“Obesity is one of the most important modifiable cancer risk factors we have. If therapies that effectively treat obesity also influence cancer risk, that could have profound implications for how we think about prevention.”

---

Dr. Aparna Kamat, gynecologic oncologist